VGI Health Technology Limited Stock Market Press Releases and Company Profile
VTL commences divestment of Invictus BioPharma Pty Ltd
VTL commences divestment of Invictus BioPharma Pty Ltd

Sydney, Aug 29, 2023 AEST (ABN Newswire) - VGI Health Technology Limited (googlechartNSX:VTL) is pleased to announce that it has been advised by Invictus BioPharma Holdings Ltd (IVBHL) that IVBHL is now in a position to commence the process of acquiring Invictus BioPharma Pty Ltd in accordance with the Share Sale Agreement approved by shareholders on 3 June 2022. Further updates will be provided as the settlement of this transaction progresses.

About VGI Health Technology Limited

VGI Health Technology LimitedVGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines. 


Glenn Tong
CEO and Managing Director
Ph: +61 (0) 412 193 350

Andrew Crook
Investor and Media Relations
Ph:+61 (0) 419 788 431

Catriona Glover
Company Secretary
Tel: +61 (0) 402 328 200

ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 18) (Last 30 Days: 67) (Since Published: 1825)